IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Matino, Davide, Gargaro, Marco, Santagostino, Elena, Di Minno, Matteo N.D., Castaman, Giancarlo, Morfini, Massimo, Rocino, Angiola, Mancuso, Maria E., Di Minno, Giovanni, Coppola, Antonio, Talesa, Vincenzo N., Volpi, Claudia, Vacca, Carmine, Orabona, Ciriana, Iannitti, Rossana, Mazzucconi, Maria G., Santoro, Cristina, Tosti, Antonella, Chiappalupi, Sara, Sorci, Guglielmo, Tagariello, Giuseppe, Belvini, Donata, Radossi, Paolo, Landolfi, Raffaele, Fuchs, Dietmar, Boon, Louis, Pirro, Matteo, Marchesini, Emanuela, Grohmann, Ursula, Puccetti, Paolo, Iorio, Alfonso, Fallarino, Francesca
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607121/
https://ncbi.nlm.nih.gov/pubmed/26426076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81859
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados